» Articles » PMID: 31492709

Regulatory T Cells in Skin Are Uniquely Poised to Suppress Profibrotic Immune Responses

Abstract

At the center of fibrosing diseases is the aberrant activation of tissue fibroblasts. The cellular and molecular mechanisms of how the immune system augments fibroblast activation have been described; however, little is known about how the immune system controls fibroblast function in tissues. Here, we identify regulatory T cells (T) as important regulators of fibroblast activation in skin. Bulk cell and single-cell analysis of T in murine skin and lungs revealed that T in skin are transcriptionally distinct and skewed toward T helper 2 (T2) differentiation. When compared with T in lung, skin T preferentially expressed high levels of GATA3, the master T2 transcription factor. Genes regulated by GATA3 were highly enriched in skin "T2 T" subsets. In functional experiments, T depletion resulted in a preferential increase in T2 cytokine production in skin. Both acute depletion and chronic reduction of T resulted in spontaneous skin fibroblast activation, profibrotic gene expression, and dermal fibrosis, all of which were exacerbated in a bleomycin-induced murine model of skin sclerosis. Lineage-specific deletion of in T resulted in an exacerbation of T2 cytokine secretion that was preferential to skin, resulting in enhanced fibroblast activation and dermal fibrosis. Together, we demonstrate that T play a critical role in regulating fibroblast activation in skin and do so by expressing a unique tissue-restricted transcriptional program that is mediated, at least in part, by GATA3.

Citing Articles

Engineered extracellular vesicles promote the repair of acute kidney injury by modulating regulatory T cells and the immune microenvironment.

Xie L, Zhang K, Pan K, Su X, Zhao X, Li R J Transl Med. 2025; 23(1):304.

PMID: 40065372 PMC: 11895318. DOI: 10.1186/s12967-025-06268-x.


Cardiac involvement in systemic sclerosis: A critical review of knowledge gaps and opportunities.

Jones X, Bottini N, Boin F, Marban E J Scleroderma Relat Disord. 2025; :23971983241313096.

PMID: 39845449 PMC: 11748146. DOI: 10.1177/23971983241313096.


Immune Dysregulation and Cellular Composition in Lichen Sclerosus Revealed by Integrative Epigenetic Analysis with Cell Type Deconvolution.

Wang J, Fan H, Bao Z, Li G, Wang L, Zhang D J Inflamm Res. 2025; 18():283-299.

PMID: 39802516 PMC: 11724625. DOI: 10.2147/JIR.S481324.


3D bioprinting of engineered exosomes secreted from M2-polarized macrophages through immunomodulatory biomaterial promotes wound healing and angiogenesis.

Dutta S, An J, Hexiu J, Randhawa A, Ganguly K, Patil T Bioact Mater. 2024; 45:345-362.

PMID: 39669126 PMC: 11636135. DOI: 10.1016/j.bioactmat.2024.11.026.


Innovative Hydrogel Design: Tailoring Immunomodulation for Optimal Chronic Wound Recovery.

Lai C, Chen W, Qin Y, Xu D, Lai Y, He S Adv Sci (Weinh). 2024; 12(2):e2412360.

PMID: 39575827 PMC: 11727140. DOI: 10.1002/advs.202412360.


References
1.
Ramalingam T, Pesce J, Sheikh F, Cheever A, Mentink-Kane M, Wilson M . Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol. 2007; 9(1):25-33. PMC: 2692551. DOI: 10.1038/ni1544. View

2.
Rubtsov Y, Rasmussen J, Chi E, Fontenot J, Castelli L, Ye X . Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008; 28(4):546-58. DOI: 10.1016/j.immuni.2008.02.017. View

3.
Birjandi S, Palchevskiy V, Xue Y, Nunez S, Kern R, Weigt S . CD4(+)CD25(hi)Foxp3(+) Cells Exacerbate Bleomycin-Induced Pulmonary Fibrosis. Am J Pathol. 2016; 186(8):2008-2020. PMC: 4973661. DOI: 10.1016/j.ajpath.2016.03.020. View

4.
Andrews A, Holloway J, Holgate S, Davies D . IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol. 2006; 176(12):7456-61. DOI: 10.4049/jimmunol.176.12.7456. View

5.
Jakubzick C, Choi E, Joshi B, Keane M, Kunkel S, Puri R . Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J Immunol. 2003; 171(5):2684-93. DOI: 10.4049/jimmunol.171.5.2684. View